Endocrine Abstracts

Radioactive iodine (RAI) has been in use for more than 60 years with satisfactory results RAI and safe profile, there has been a different outcome of treatment in different ethnic groups. We assessed the demographic features and clinical outcome of a Jordanian and British cohorts of patients treated with RAI.

Methods: Hyperthyroid patients who opted RAI as a primary therapy and those who had relapse after treatment with antithyroid drugs (ATD) or had significant side effects. All patients were advised to stop ATD 3–5 days before RAI dose and special precautions to avoid contact with others according to international standards were fully explained. Thyroid function tests were checked every 12 weeks for the first year after RAI dose. Clinical outcome of euthyroidism, hypothyroidism or persistent hyperthyroidism after at least one year of FU were reported and doses of RAI were compared.

Results: There were 242 patients who received 258 doses of RAI in the Jordanian cohort and 234 in the British cohort.

The demographic features and clinical out come are shown in table 1.

Discussion and conclusion: There was a significant difference in the hypothyroid and euthyroid rates between the two cohorts being better in the British cohort,while the relapse rate was significantly lower in the Jordanian cohort.The interpretation might be in the dose delivered to the Jordanian cohort was higher. More patients in the Jordanian cohort received ATD that might affect the final outcome.